Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Izuralimab |
| Trade Name | |
| Synonyms | XmAb 23104|XmAb23104 |
| Drug Descriptions |
Izuralimab (XmAb23104) is a bispecific antibody that binds to PD-1 (PDCD1) and ICOS (inducible T-cell costimulator, CD278), potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2784). |
| DrugClasses | ICOS Antibody 6 PD-L1/PD-1 antibody 132 |
| CAS Registry Number | 2329669-80-7 |
| NCIT ID | C157578 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Izuralimab | Izuralimab | 0 | 2 |
| Izuralimab + XmAb22841 | Izuralimab XmAb22841 | 0 | 1 |